Dr. Molloy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Euclid Ave
# 9500
Cleveland, OH 44195Phone+1 216-444-0646Fax+1 216-445-7569
Education & Training
University College of Dublin National Univ SOMClass of 1997
Clinical Trials
- Temporal Artery Biopsy vs ULtrasound in Diagnosis of GCA (TABUL) Start of enrollment: 2010 Jun 01
- American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis Start of enrollment: 2011 Jan 01
Publications & Presentations
PubMed
- 1 citationsRisk loci involved in giant cell arteritis susceptibility: a genome-wide association study.Gonzalo Borrego-Yaniz, Lourdes Ortiz-Fernández, Adela Madrid-Paredes, Martin Kerick, José Hernández-Rodríguez
The Lancet. Rheumatology. 2024-06-01 - Characteristics and burden of disease in patients with radiographic versus non-radiographic axial spondyloarthritis in the ASRI cohort.Sean Quinn, Sinead Maguire, Finbar O'Shea, Lorraine O'Neill, Eamonn Molloy
Irish Journal of Medical Science. 2024-02-01 - 57 citationsEfficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.Maria C Cid, Sebastian H Unizony, Daniel Blockmans, Elisabeth Brouwer, Lorenzo Dagna
Annals of the Rheumatic Diseases. 2022-05-01
Authored Content
- Ustekinumab for Refractory Giant Cell Arteritis: A Prospective 52-Week TrialApril 2018
- Ustekinumab for Refractory Giant Cell Arteritis: A Prospective 52-Week TrialApril 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
